Blueprint Medicines CEO Jeffrey Albers' 2018 pay jumps 97% to $9.7M
Blueprint Medicines reports 2018 executive compensation
By ExecPay News
Published: April 29, 2019
Blueprint Medicines reported fiscal year 2018 executive compensation information on April 29, 2019.
In 2018, six executives at Blueprint Medicines received on average a compensation package of $3.9M, a 85% increase compared to previous year.
Average pay of disclosed executives at Blueprint Medicines
Jeffrey W. Albers, Chief Executive Officer, received $9.7M in total, which increased by 97% compared to 2017. 91% of Albers' compensation, or $8.9M, was in option awards. Albers also received $310K in non-equity incentive plan, $541K in salary, as well as $8.3K in other compensation.
For fiscal year 2018, the median employee pay was $398,087 at Blueprint Medicines. Therefore, the ratio of Jeffrey W. Albers' pay to the median employee pay was 24 to one.
Christina Rossi, Chief Commercial Officer, received a compensation package of $3.7M. 87% of the compensation package, or $3.3M, was in option awards.
Anthony Boral, Chief Medical Officer, earned $2.7M in 2018, a 61% increase compared to previous year.
Tracey L. McCain, Chief Legal and Compliance Officer, received $2.6M in 2018, which increases by 279% compared to 2017.
Kathryn Haviland, Chief Operating Officer, earned $2.6M in 2018, a 78% increase compared to previous year.
Michael Landsittel, Chief Financial Officer, received $1.7M in 2018, which increases by 107% compared to 2017.
Related executives
Jeffrey Albers
Blueprint Medicines
Chief Executive Officer
Michael Landsittel
Blueprint Medicines
Chief Financial Officer
Anthony Boral
Blueprint Medicines
Chief Medical Officer
Tracey McCain
Blueprint Medicines
Chief Legal and Compliance Officer
Christina Rossi
Blueprint Medicines
Chief Commercial Officer
Kathryn Haviland
Blueprint Medicines
Chief Operating Officer
You may also like
Source: SEC filing on April 29, 2019.